12hon MSN
Trump’s move to cut Ozempic and Wegovy prices could backfire with a $35 billion cost during shutdown
Donald Trump's move to cut drug prices in America can potentially turn out to be a $35 billion additional cost to the federal ...
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.
Investor's Business Daily on MSN
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera
Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech ...
Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback